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Abstract Substantial evidence points to melatonin as
playing a role in the regulation of circadian rhythms, sleep,
and headache disorders. The objective of the study was to
assess 6-sulphatoxymelatonin (aMT6s) levels in a large
consecutive series of patients with migraine, comparing
with controls. A total of 220 subjects were evaluated—146
had migraine and 74 were control subjects. Urinary sam-
ples were collected into the same plastic container since
8:00 p.m. to 8:00 a.m. of the next day (12-h period) and
aMT6s was measured with quantitative ELISA technique.
Among patients with migraine, 53% presented pain on the
day of the urine samples collection. Their urinary aMT6s
concentration was significantly lower than in the urine
of patients without pain [14.0 ± 7.3 vs. 49.4 ± 19.0;
t(143) = -15.1; 95% CI = -40.0 to -30.8; P \ 0.001].
There was no significant difference in the aMT6s concen-
tration of patients with migraine without pain on the day of
their urine samples collection and controls [49.4 ± 19.0 vs.
42.5 ± 27.9; t(140) = 1.7; 95% CI = -1.2 to 14.8;
P = 0.094]. To our knowledge, this is the first study to
demonstrate reduction in melatonin levels during attacks in
episodic and chronic migraine.
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Introduction
The hypothalamus is thought to play an important role in
migraine pathogenesis [1–4]. It is possible that periodic
central disturbance of hypothalamic activity or labile
threshold could account for the periodicity of the migraine
attack. It also provides a mechanism by which emotional
disturbances could be mediated by pathways from the
limbic system to the hypothalamus [5]. Almost 60% of
patients with migraine report symptoms of elation, irrita-
bility, depression, hunger, thirst, or drowsiness during the
24 h preceding headache, which also suggests a hypotha-
lamic site of origin [4].
It has been suggested that if neuronal hyperexcitability
and cortical spreading depression during migraine attack
are part of the pathophysiology of the disorder, then aura is
not the initiating event but rather is initiated by subcortical
changes [6]. The suprachiasmatic nucleus (SCN) is a pos-
sible subcortical origin of this changes, suggesting that a
migraine attack might be an attempt at a drastic resetting of
the biological clock in response to its previous decom-
pensation [4].
Compared with the environmental cycle of 24 h, the
human biological pacemaker has an intrinsic periodicity of
25.7 hours [7]. The conversion between the intrinsic
rhythm and the environmental rhythm is known as
‘‘entrainment’’. The environmental agents that are able to
synchronize the endogenous circadian clock are known as
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‘‘zeitgebers’’, among them the most influential is the
change in luminosity between day and night [8]. Photic
entrainment is mainly mediated by a direct retinal-hypo-
thalamic pathway that conveys to the SCN information
about the level of ambient light. Photic information relayed
from the SCN to the pineal gland is closely reflected there
in the secretion of melatonin, which is probably the
strongest biological marker of the circadian rhythm in
humans [4].
Melatonin is absent during the day in human beings [9]
and its nocturnal secretion is the main biological event
signaling to the organism when it is night [10]. Once
melatonin is synthesized in the pineal gland, it is quickly
released, generating a blood melatonin rhythm reminiscent
of that seen in the gland. Being an amphiphilic molecule,
melatonin is capable of entering every cell in the organism;
additionally, it readily crosses all morphophysiological
barriers, including the blood–brain barrier and the placenta.
Melatonin is enzymatically-degraded in the liver to 6-hy-
droxymelatonin and finally excreted in the urine as 6-
sulphatoxymelatonin (aMT6s) [10]. Urine analysis is
widely used as a measure of melatonin secretion, since it is
correlated with the nocturnal profile of plasma melatonin
secretion [11]. The advantages of urinary metabolite
measurement are substantial, particularly the non-invasive
nature of fluid collection, the ability to perform very long-
term studies and the feasibility of studies in circumstances
where blood sampling is difficult.
Substantial evidence points to melatonin as playing a
role in the regulation of circadian rhythms, sleep, and
headache [12]. An interictal decrease in the levels of
nocturnal plasma melatonin[13] and an alteration of the
urinary aMT6s excretion throughout the ovarian cycle have
also been described in migraine patients [14, 15]. Fur-
thermore, seasonal variations in daily melatonin secretion
have been reported, patients with migraine being more
likely to have headache during the bright Arctic summer
season [16, 17].
These data prompted us to test the hypothesis of
decreased levels of melatonin during migraine attacks,
assessing aMT6s levels in a large consecutive series of
patients with migraine, comparing with controls.
Materials and methods
The study was performed from February to December
2006, at Albert Einstein Hospital, Sa˜o Paulo, Brazil. The
inclusion criteria were: patients with migraine and controls
subjects of both sex, aged 18–65 years, able to understand
the consent form and explanations given by the research
team, and with satisfactory diuresis. Migraine was defined
according to International Classification of Headache
Disorders diagnostic criteria, Second edition [18]. The
control subjects did not have migraine or any other primary
headache. The exclusion criteria were: chronic diseases,
instable medical condition, secondary headache, continu-
ous usage of any kind of medication, drug addiction or
alcohol abuse. The patients who remained aroused with
light exposure during the night of urine collection were
also excluded. All subjects provided written consent for the
experimental procedure approved by the local ethics
committee (Federal University of Sa˜o Paulo and Albert
Einstein Hospital, Sa˜o Paulo, Brazil).
Subjects were asked to collect urine into a plastic con-
tainer from 8:00 p.m. to 8:00 a.m. of the next day (12-h
period). Female patients were advised to collect the sam-
ples at least 5 days away from the beginning or the end of
menses. The patients were asked to provide information
regarding the presentation or not of a migraine headache on
the day of urine collection.
Sample’s volumes were recorded and 5-ml aliquots were
stored frozen at -20C until analysis. aMT6s has been
found to be extremely stable without preservative for at
least 5 days at room temperature and for at least 2 years at
-20C and no special precautions were necessary during
sample collection [19]. aMT6s was measured by quanti-
tative ELISA (Bu¨hlmann Laboratories, Allschwil,
Switzerland). At a dilution of 1:200, 50 ll of urine sample
was assayed directly; where necessary, samples were re-
assayed at dilution of 1:400.
Data analysis
The chi-square test (v2) (without Yates correction) was
used for categorical data comparisons. Mean differences of
continuous measurements were tested by the Student’s t
test (t) followed by the Mann–Whitney test, which without
exception did not show any discrepant results (only the
parametric tests’ results will be reported). The Pearson’s
product-moment correlation coefficient (r) was used to
assess the relationship between two continuous variables.
A P value of less than 0.05 was considered to indicate
statistical significance; all tests were two-tailed. Ninety-
five percent confidence intervals (CI) were calculated for
the difference between means. All statistical analyses were
performed on a personal computer with the statistical
package SPSS 11.5.1 for Windows.
Results
A total of 268 subjects were referred to evaluation. From
this total, 48 were excluded: 12 patients did not correctly
provide their urine samples, 3 refused to take part in the
study, 19 did not give reliable headache information and 17
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had at least one exclusion criteria. The remaining 220
subjects were in accordance with inclusion criteria. Among
them, 146 had migraine and 74 were control subjects.
There were no statistically significant differences
between controls and patients with migraine regarding the
mean age [38.4 ± 9.0 vs. 38.5 ± 11.2, t(218) = -0.7,
95% CI = -3.0 to 2.8, P = 0.946] and sex [78 vs. 81% of
women, v2(1) = 0.18; P = 0.669].
Among patients with migraine, 53% presented pain on
the day of the urine samples collection. Their urinary
aMT6s concentration was significantly lower than in the
urine of patients without pain [14.0 ± 7.3 vs. 49.4 ± 19.0;
t(143) = -15.1; 95% CI = -40.0 to -30.8; P \ 0.001].
However, there was no significant difference in the aMT6s
concentration of patients with migraine without pain on the
day of their urine samples collection and controls [49.4 ±
19.0 vs. 42.5 ± 27.9; t(140) = 1.7; 95% CI = -1.2 to
14.8; P = 0.094] (Fig. 1).
Migraine with aura was observed in 24% of the patients.
There was no significant difference in the aMT6s concen-
tration of patients with migraine with and without aura
[32.3 ± 21.5 vs. 30.5 ± 22.9; t(144) = -0.52; 95% CI =
-10.9 to 6.4; P = 0.604].
Discussion
Claustrat et al. [13] were the first to demonstrate lower
plasma melatonin levels in samples from migraine patients
compared with controls. Migraine patients without
depression had lower levels than controls, but migraineurs
with superimposed depression exhibited the greatest mel-
atonin deficiency. Murialdo et al. [15] also found nocturnal
urinary melatonin to be significantly decreased throughout
the ovarian cycle of migraine patients without aura com-
pared with controls. During the luteal phase, when
melatonin levels should normally increase, migraine
patients showed a less pronounced change when compared
with controls. Melatonin excretion was further decreased
when patients suffered a migraine attack.
Brun et al. [14] studied urinary melatonin in women
with migraine without aura attacks associated with menses
and controls. Melatonin levels throughout the cycle were
significantly lower in the migraine patients than in controls.
In the control group, melatonin excretion increased sig-
nificantly from the follicular to the luteal phase, whereas no
difference was observed in the migraine group.
Peres et al. [20] studied plasma melatonin nocturnal
profile in chronic migraine patients and controls. Lowered
melatonin levels in patients with insomnia were observed
compared with those without insomnia, and a phase delay
in the melatonin peak in patients versus controls.
To our knowledge, our study is the first to demonstrate
reduction in melatonin levels during migraine attacks, not
depending on the migraine type. However, patients with
migraine that did not present headache in the day of the
urine sample collection did not have lower aMT6s levels
when compared with controls. In our opinion, two possible
explanations could be made to this fact: first, the hypo-
thalamic disturbance may occur only during attacks,
mainly in the prodromal phase, so patients in the interictal
period will not have reduction of melatonin levels. The
other possible explanation is that all patients with migraine
could have lower levels of aMT6s, but patients in the
interictal phase could have a compensatory increase in
melatonin levels. These results support hypothalamic
involvement in migraine pathophysiology.
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